(PharmaNewsWire.Com, July 03, 2019 ) The global epigenetics market is projected to reach USD 1.60 billion by 2022 from USD 0.85 billion in 2016, at a CAGR of 13.3%
The Research report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the Epigenetics Market, along with revenue estimates & forecasts and market share analysis.
Moreover, the study showcases back-to-back parameters like application, improvement, product growth, and diverse structures & key processes. The report highlights the in-depth analysis of various critical parameters such as profit & loss statistics, product value, production capability, production process, and many more.
The decreasing sequencing costs and time, increase in research activities to identify and develop inhibitors/drugs for various diseases, funding for epigenetics research, and rising prevalence of cancer are the major factors driving the growth of this market.
The Major Players Opearting in the Epigenetics Market are:
The major players in the global epigenetics market are Illumina (US), Thermo Fisher (US), Diagenode (Belgium), QIAGEN (Netherlands), Merck Millipore (US), Abcam (UK), Active Motif (US), New England Biolabs (US), Agilent (US), Zymo Research (US), PerkinElmer (US), and Bio-Rad (US).
Illumina dominated the global epigenetics market in 2016. The company provides sequencing and array-based solutions for genetic analysis. It develops, manufactures, and markets integrated systems and life science tools for the analysis of genetic variation and biological function.
Illumina operates through 26 subsidiaries located in the US, the UK, and other countries in Europe and the Asia Pacific regions. In order to achieve high growth and increase its customer base, the company focuses on organic and inorganic strategies such as product launches, collaborations, and agreements.
Geographical Detailed Analysis of Epigenetics Market:
North America accounted for the largest share of the epigenetics market in 2016, followed by Europe.
Increase in epigenetics research activities, favorable government funding initiatives, high R&D expenditure, rising incidence of various diseases, and the presence of key players in the region are the key factors driving the growth of the epigenetics market in North America.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
